Inhibition of p53-Dependent, but Not p53-Independent, Cell Death by U19 Protein from Human Herpesvirus 6B

Citation for published version:
Kofod-olsen, E, Moller, JML, Schleimann, MH, Bundgaard, B, Bak, RO, Oster, B, Mikkelsen, JG, Hupp, T & Hollsberg, P 2013, 'Inhibition of p53-Dependent, but Not p53-Independent, Cell Death by U19 Protein from Human Herpesvirus 6B' PLoS One, vol 8, no. 3, pp. e59223. DOI: 10.1371/journal.pone.0059223

Digital Object Identifier (DOI):
10.1371/journal.pone.0059223

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS One

Publisher Rights Statement:
Copyright: © 2013 Kofod-Olsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Inhibition of p53-Dependent, but Not p53-Independent, Cell Death by U19 Protein from Human Herpesvirus 6B

Emil Kofod-Olsen¹, Janni M. L. Møller¹, Mariane H. Schleimann¹, Bettina Bundgaard¹, Rasmus O. Bak¹, Bodil Øster¹,², Jacob G. Mikkelsen¹, Ted Hupp², Per Höllsberg¹* ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Institute of Genetics and Molecular Medicine, Cancer Research UK p53 Signal Transduction Laboratories, University of Edinburgh, Edinburgh, Scotland, United Kingdom

Abstract
Infection with human herpesvirus (HHV)-6B alters cell cycle progression and stabilizes tumor suppressor protein p53. In this study, we have analyzed the activity of p53 after stimulation with p53-dependent and -independent DNA damaging agents during HHV-6B infection. Microarray analysis, Western blotting and confocal microscopy demonstrated that HHV-6B-infected cells were resistant to p53-dependent arrest and cell death after γ irradiation in both permissive and non-permissive cell lines. In contrast, HHV-6B-infected cells died normally through p53-independent DNA damage induced by UV radiation. Moreover, we identified a viral protein involved in inhibition of p53 during HHV-6B-infection. The protein product from the U19 ORF was able to inhibit p53-dependent signaling following γ irradiation in a manner similar to that observed during infection. Similar to HHV-6B infection, overexpression of U19 failed to rescue the cells from p53-independent death induced by UV irradiation. Hence, infection with HHV-6B specifically blocks DNA damage-induced cell death associated with p53 without inhibiting the p53-independent cell death response. This block in p53 function can in part be ascribed to the activities of the viral U19 protein.

Introduction
Human herpesvirus (HHV)-6B is a ubiquitous herpesvirus in humans with a seroprevalence close to 95% [1,2]. Infection usually occurs within the first two years of life, after which HHV-6B remains as a lifelong latent infection [3,4]. Unlike other known herpesviruses, it has been suggested that latency is accompanied by integration of the viral genome into the host cell genome [5]. This has led to establishment of chromosomal integration of HHV-6B into all cells in approximately 1% of individuals [6]. Primary infection is the cause of the common childhood disease exanthem subitum [7] and may give rise to episodes of febrile seizure [8]. The virus reactivates later in life, and might lead to severe and sometimes fatal disease in immune compromised individuals [9]. Moreover, HHV-6B infection has been associated with various diseases, including mesial temporal lobe epilepsy [10].

Upon a viral infection, the cell elicits a series of antiviral activities, including activation of the tumor suppressor protein p53. This protein is a key element in controlling the response to different forms of genotoxic stress resulting in the induction of arrest and repair. If the stress persists, this may be followed by programmed cell death through the intrinsic pathway [11–15]. The direction of activity of p53 is managed through a wide range of post-translational modifications [16]. During cellular stress such as DNA damage or viral infection, the cell can quickly increase the amount of p53 and try to either repair the damage or induce cell death if the damage is consistent or irreparable. To establish a viral infection, it is therefore of utmost importance for the virus to either prevent the activities of p53 completely or to alter p53 activities to help shape an infection-friendly environment through DNA damage repair mechanisms.

Most herpesviruses have evolved mechanisms to inhibit or alter p53-dependent actions [17–20]. One of the most studied systems involves the beta-herpesvirus human cytomegalovirus (HCMV) and its murine counterpart (MCMV). During infection with HCMV, the levels of p53 rise early during infection. This rise in p53 levels is in part due to translocation of the negative inhibitor MDM2 to the cytoplasm where it is degraded [18,21]. The high level of p53 during early HCMV-infection is transcriptionally active and it is suggested that the virus needs p53 as a transcription factor during the early parts of the infection [22,23]. Another human beta-herpesvirus that is known to interfere with the p53 network is human herpesvirus (HHV)-6B. Others and we have previously shown that p53 accumulates in the cytoplasm after HHV-6B infection [24–26].

Although extensively studied in many other viruses, the regulation and activity of p53 during HHV-6B infection still remain largely unknown. In this report, we show that HHV-6B infection prevents p53-dependent, but not -independent cell death. Moreover, we show that the accumulation of p53 observed during HHV-6B infection can in part be ascribed to the protein product from the U19 ORF. Expression of this protein inhibited p53 activity and induction of PUMA and apoptosis in a manner similar to that observed during HHV-6B infection.
Materials and Methods

Cells and Virus

The human epithelial colon carcinoma cell line HCT116 [27] was a gift from B. Vogelstein and K. W. Kinzler. HCT 116 cells were cultured in McCoy’s 5A medium, the human embryonic kidney cell line 293T (ATCC) was cultured in Dulbecco’s modified Eagle’s medium (DMEM), and the human leukemia T-cell line MOLT3 [28] (a gift from Z. Berneman) was cultured in RPMI medium. All media were supplemented with 10% fetal calf serum, glutamine (0.2 g/L), streptomycin (0.2 g/L), penicillin (0.2 g/L) and HEPES (10 mM). HHV-6B strain PL-1 was propagated in MOLT3 cells, and virus was concentrated by ultracentrifugation, as previously described [29]. The viral titer was determined by TCID50 using a thymidine incorporation assay 4 hpi, as previously described [30].

Induction of Cell Death

Cells exposed to γ radiation were treated with a cesium γ-source for 15 minutes, equivalent to 30 Gy, followed by additional culture for 24 hrs before use. Cells exposed to UV radiation were treated with UV-C light (15 Watt) in minimal amounts of media for 5 sec to 10 min, as indicated, and cultured as indicated. Cells treated with leupeptin (Sigma-Aldrich, Milwaukee, WI), doxorubicin (Sigma Aldrich), or MG132 (Sigma Aldrich) were incubated 24 hrs in 10 μM leupeptin, 0.2 μg/ml doxorubicin, or 10 μM MG132 before use.

Intracellular ATP Measurements

Cell viability was assessed by measuring intracellular ATP levels using the CellTiter-Glo® Luminescent Cell Viability Assay according to the manufacturer’s description (Promega). The percentage of dead cells was calculated by the drop in ATP level in treated cells relative to untreated cells. Cells treated with zVAD, or MG132 (Sigma Aldrich) were incubated 24 hrs with 50 μM zVAD-fmk (R&D systems, UK) and necrostatin-1 (30 μM) (Sigma Aldrich) were incubated for 1 hr prior to γ or UV irradiation.

Luciferase Measurements

HCT116 cells wildtype (wt) and U19-S cells were transfected with the WWP-luciferase plasmid containing wt WAF1 (p21) promoter with p53 binding sites using the Amaxa transfection system. Luciferase intensity was measured 48 hrs post transfection with the Luciferase 1000 assay system (Promega, Madison, WI, USA) on an Ascent Luminoskan.

Lentiviral Production

Lentiviral vectors were produced in 293T cells that were seeded in 10-cm dishes (4×10⁶ cells/dish) in DMEM. Twenty-four hrs later, transfections were performed using standard calcium phosphate precipitation of the indicated plasmids into the producer cells (3.75 μg pMD2.G, 3 μg pRSV-Rev, 13 μg pMDGP-Lg/RRE, and 13 μg lentiviral transfer vector). Twenty-four hrs post-transfection the medium was removed and McCoy’s 5A medium was added. Forty-eight hrs post-transfection, the viral supernatant was harvested and filtered through 0.45 μm filters (Sartsted, Numbrecht, Germany) and supplemented with 8 μg/ml polybrene (Sigma-Aldrich). In transduction studies, HCT116 cells were seeded in 6-well plates (5×10⁵ cells/well). Twenty-four hrs later, the cells were transduced with the lentiviral vectors: HCT116 cells were washed with PBS and incubated with crude lentiviral vectors diluted two-fold in McCoy’s 5A medium. The medium was changed 24 hrs post-transduction.

Microarray Analysis

Affymetrix GeneChip Human Genome U133 plus 2.0 Array was used to examine expression of mRNA from the cells. HCT116 wt cells, HCT116-p53−/− cells, and HHV-6B-infected HCT116 cells (24 hrs) were treated with or without 30 Gy γ radiation and left for additional 4 hrs before total RNA preparation. Total RNA was prepared using RNezol B (Gibco, Brl, California, USA), as described by the manufacturer. The RNA quality was examined by analysis on a 2100 Bioanalyzer (Agilent) to verify that samples had a 28S/18S ratio higher than 1 and RNA integrity number higher than 7. Total RNA was reverse transcribed and labeled before hybridized to the Human Genome U133 plus 2.0 GeneChip overnight before scanning. For analysis, 128 known p53-response genes and apoptotic marker genes were analyzed using the microarray dataset. The genes lacking significant signals in all cell types/treatment groups were excluded from the analyses. The remaining genes were grouped according to mRNA expression level using hierarchical clustering. Red boxes represent genes with high mRNA expression and blue boxes represent genes with low mRNA expression. The clustering algorithm and heat map was performed using GenePattern software.

Confocal Microscopy

Cells (10⁶) were transferred to poly-L-lysine coated slides and incubated for 24 hrs followed by fixation in 4% formalin/PBS (pH 7.5). Cells were washed twice in PBS, blocked in 5% BSA/PBS and permeabilized in 0.2% Triton-X 100/PBS. P53 was visualized using a rabbit anti-p53 pAb (FL393) (1:200) (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), mouse anti-p53 mAb (DO-7) (1:200) (Life Technologies Europe BV) mouse anti-p53-phospho-Ser15 [p-Ser15] mAb (1:1000) (Cell Signaling Technology, Beverly, MA, USA), p41 was visualized using anti-p41 mAb (1:400) (Advanced Biotechnologies, Tebu-Bio, Columbia, USA), DR6 was visualized using a rabbit anti-DR6 peptide pAb (1:200) (GeneScript – custom antibody [25]), active caspase-3 was visualized using a rabbit anti-p17-fragment mAb (1:100) (Abcam, UK). Secondary antibodies were F(ab')2 antibody fragment conjugated with Alexa488 or Alexa546 (1:400) (Life Technologies). The nucleus was visualized by incubating the cells in DAPI (300 nM)/PBS for 15 min. Imaging was carried out using the 488 nm line of a multi-line argon laser, the 543 nm line of a green helium-neon laser and the 405 nm line of a violet diode laser in a Zeiss LSM710 inverted microscope with a 63x oil-immersion objective.

Western Blot Analyses

Cells were lysed for 30 min on ice in 1x Lysis Buffer (Cell Signaling) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM sodium fluoride (NaF) and Complete Mini Protease Inhibitor (Roche Diagnostics Scandinavia AB, Hvidovre, Denmark). Nuclear and cytoplasmic fractions were generated using the Nuclear Extract Kit (Active Motif, Rixensart, Belgium). Proteins were separated on Criterion 12% BIS-TRIS gels (Bio-Rad, Copenhagen, Denmark), blotted to nitrocellulose membranes and visualized with the following antibodies: Rabbit anti-PARP mAb (1:2000) (Cell Signaling), rabbit anti-GAPDH pAb(1:1000) (Santa Cruz), mouse anti-RCC1 mAb (1:1000) (Abcam), mouse anti-p53 mAb (DO-7) (1:1000) (Cell Signaling), mouse anti-p53-phospho-Ser15 [p-Ser15] mAb (1:1000) (Cell Signaling), mouse anti-p53-phospho-Ser46 [p-Ser46] mAb (1:1000) (Cell Signaling), mouse anti-HHV-6 mAb (7G7) (1:1000) (Argene Bioskop, Verniolle, France), Secondary antibodies were horseradish peroxidase-conjugated swine anti-rabbit pAb (PO217) (1:2000) (DAKO, Glostrup, Denmark), horseradish peroxidase-conjugated rabbit anti-mouse pAb (A481) (1:2000) (DAKO, Glostrup, Denmark).
anti-mouse pAb (1:2000) (P0260, DAKO). Membranes were developed with Chemiluminescence reagent (Pierce, Thermo Scientific, Slangerup, Denmark). All antibodies were used in 5% skimmed milk.

**Cell Cycle Analysis**

Cells (10^6 per sample) were treated with trypsin, washed twice in PBS and resuspended in 200 μl PBS in 96-well microtiter plates. Nuclear Isolation and Stain (NIM-DAPI) (Beckman Coulter Inc., Brea, CA, USA) was added to each sample, and the nuclei were analysed by flow cytometry using the 350 nm ultra-violet laser on a Quanta SC MHL flow cytometer (Beckman Coulter Inc.). The data were analysed using FlowJo software with the Dean-Jett-Fox algorithm [31].

**Real-time PCR**

RNA was extracted from 10^6 cells using RNeasy mini kit (Qiagen Nordic, Sollentuna, Sweden). Real time PCR was performed on a Stratagene Mx3005P with the following primers: TBP: 5'-GCCGTGTGCTGCGGTAAT-3' and 5'-GAGACAAGAGGAGCAGCA-3'; MDM2: 5'-ACCACCTCACAGATTCCA-3' and 5'-CAGGCCCAAACAAATGTCCG-3'; PUMA (BBC3): 5'-GAGACAAGAGGAGCAGCA-3' and 5'-ACATGCTGTCAGAGAAGT-3' (GATCopenhagen, Copenhagen, Denmark). PUMA and MDM2 mRNA levels were determined relative to TBP mRNA using the formula: 2^((Ct1/Ct2)).

**Results**

**HHV-6B Inhibits p53-dependent, but not p53-independent, Cell Death**

During infection with HHV-6B, p53 is stabilized and accumulates massively in the cytoplasm of infected T cells [24,26]. It has, however, not been examined if p53 continually stays in the cytoplasm as the infection progresses. We infected MOLT3 cells with HHV-6B (PL-1 strain) for 24, 48, and 72 hrs and analyzed the localization of p53 and the viral DNA-polymerase cofactor protein p41 using confocal microscopy. This analysis showed a cytoplasmic accumulation of p53 during HHV-6B infection at all analyzed time points (Figure 1A). We have previously examined HHV-6B infection of the non-permissive HCT116 cell line [32,33]. To verify that p53 accumulation was also predominantly cytoplasmic during infection of these cells, we infected them with HHV-6B for 48 hrs and analyzed the localization of p53 with confocal microscopy. This demonstrated that p53 accumulated virtually completely in the cytoplasm, whereas doxorubicin treatment led to nuclear accumulation, as expected (Figure 1B). Thus, in both MOLT3 and HCT116 cells, HHV-6B infection causes p53 stabilization and accumulation. Both of these cell types appear to be affected at a similar rate, but may differ in their ability to shed virus into the supernatant [32,33]. To further address this we analyzed UV-induced cell death quantitatively by measuring intracellular ATP-levels in dose-response measurements using low-dosage UV (Figure 2E). This experiment showed that UV-induced cell death was reduced in HHV-6B-infected cells under treatments below 40 J/cm^2, but the cells still died in a dose-dependent manner even at very low doses. As expected, the infected cells were rescued from γ radiation-induced death (Figure 2F).

To examine whether or not the infected cells showed any p53 response after stimulation, we treated HCT116 cells with or without HHV-6B for 24 hrs followed by γ radiation (30 Gy) and an additional 24 hrs of incubation. The cells were analyzed by Western blotting with antibodies against PARP and p53 as well as antibodies against the protein product of the p33 response-genes PUMA and p21 (Figure 2F). Both p21 and PUMA protein levels were elevated in the mock-treated cells after γ radiation, but HHV-6B infection of the cells inhibited this upregulation.

To visualize that apoptotic cells were uninfected, HCT116 cells were incubated with or without HHV-6B for 24 hrs, γ-irradiated (30 Gy) followed by incubation for 24 hrs. Confocal microscopy using antibodies against the viral protein DR6 and active caspase-3, and the DNA dye DAPI (Figure 2G) demonstrated that no DR6 positive cells showed apoptotic morphological signs, which was in contrast to the majority of uninfected cells. Cells positive for DR6 were also negative for active caspase-3 (Figure 2G).

**DNA Damage does not Activate p53 in HHV-6B-infected Cells**

We have previously shown that p53 is phosphorylated at Ser15, Ser20, Ser33, and Ser392 during HHV-6B infection [24,36]. Phosphorylation of Ser46, by HIPK2 and DYRK2 is thought to
Figure 1. HHV-6B infection leads to cytoplasmic accumulation of p53. (A) Confocal microscopy images of MOLT3 cells infected with HHV-6B for 24, 48 or 72 hrs. The cells were analyzed with antibodies against p53 (Alexa488 green), p41 (Alexa546 red) and DAPI (blue). (B) Confocal microscopy images of HCT116 cells treated with or without doxorubicine or infected with HHV-6B for 48 hrs, followed by analysis with antibodies against p53 (red), p41 (green) and DAPI (blue). (C) Heat-map showing hierarchical cluster analysis on 128 p53-target genes. Red indicates high expression and blue indicates low expression. The symbol denotes a cluster (c1 and c2) that responds to γ radiation in the wt cells, but with no or impaired response in the HHV-6B-infected cells and p53−/− cells. (D) Functional distribution of genes from c1 and c2 in the heat-map analysis in (C). Cell death, 24.1%; Proliferation, 13.1%; Arrest/Repair, 31.1%; Other, 31.1%.

doi:10.1371/journal.pone.0059223.g001
be essential for p53-induced apoptosis by increasing the binding affinity to promoters of pro-apoptotic genes [37,38]. To determine if the inability to undergo p53-dependent apoptosis could be due to lack of Ser46 phosphorylation, we infected HCT116 cells for 24, 48, or 72 hrs and analyzed the level of Ser46 phosphorylation. Surprisingly, p53 was excessively phosphorylated at this serine residue during infection (Figure 3A), a phosphorylation that has been suggested to destine the cells for apoptosis [37].

![Figure 2. HHV-6B infection rescues cells from p53-dependent apoptosis. (A & B) Western blot analysis of PARP cleavage in cells either mock-treated or infected with HHV-6B for 48 hrs. The cells were subsequently treated with mock, leupeptin (10 μM), UV radiation (10 min exposure followed by 4 hrs of incubation), doxorubicin (0.2 μg/ml for 24 hrs), γ radiation (30 Gy followed by 24 hrs of incubation), or MG132 (10 μM). 7C7 was used as infection control and GAPDH was used as loading control. (C & D) Western blot analyses with antibodies against PARP, GAPDH, and 7C7 (infection control) on lysates from HCT116 (C) or MOLT3 (D) cells treated with varying doses of UV radiation (10, 20, 240, 600 J/cm²) followed by 4 hrs of incubation. (E) ATP cell viability assay on MOLT3 cells with or without HHV-6B infection and treated with varying amounts of UV (0, 2.5, 5, 10, 15, 20, 40 and 60 J/cm²) followed by 4 hrs of incubation or γ radiation (0 and 30 Gy) followed by 24 hrs of incubation. (F) Western blot analyses with antibodies against PARP, p53, PUMA, p21 or GAPDH (loading control) on lysates from HCT116 cells either mock-treated or infected with HHV-6B for 24 hrs followed by γ radiation (30 Gy) and 24 hrs of incubation. (G) Confocal microscopy images of HCT116 cells either mock-treated or infected with HHV-6B for 24 hrs, γ-irradiated (30 Gy) followed by 24 hrs of incubation. The cells were analyzed for cleaved caspase-3 (Alexa 488 green), DR6 (Alexa 546 red), and DAPI (blue).

doi:10.1371/journal.pone.0059223.g002
Figure 3. HHV-6B infection leads to nuclear accumulation of phosphorylated p53. (A) Western blot analyses of HCT116 cells infected for 24, 48, or 72 hrs and analyzed with antibodies against p53 p-Ser15, p53 p-Ser46, p53, 7C7 (infection control), or GAPDH (loading control). (B) Western blot analyses of nuclear (NF) and cytoplasmic (CF) fractions from mock-treated or HHV-6B-infected HCT116 cells (48 hpi). The membranes were stained with antibodies against p53, p53 p-Ser46, 7C7 (infection control), RCC1 (nuclear control), or GAPDH (cytoplasmic control). (C) Western blot analyses of HCT116 cells mock-treated or HHV-6B-infected for 24 hrs followed by γ irradiation (30 Gy) and additional incubation for 24 hrs. The membrane was probed with antibodies against p53, p53 p-Ser15, or GAPDH (loading control). Numbers at the bottom of the figure indicate fold induction of Ser15 phosphorylation relative to GAPDH. (D & E) Confocal microscopy on MOLT3 cells infected with HHV-6B for 24 hrs followed by staining with antibodies against the viral protein p41 (green), p53 (red) DAPI (blue). The p53 antibodies were either the monoclonal DO-7 (D) or a polyclonal antibody (FL393) (E). Arrows point to nuclear p53 staining. (F) Confocal microscopy on MOLT3 cells infected with HHV-6B for 24 hrs followed by staining with antibodies against p53 phospho-Ser20 (green), 7C7 (red) and DAPI (blue). (G) Confocal microscopy on MOLT3 cells infected with HHV-6B for 24 hrs, γ-irradiated (30 Gy) for 24 hrs followed by staining with antibodies against the viral protein DR6 (green), p53 (DO-7) (red) DAPI (blue).

doi:10.1371/journal.pone.0059223.g003
After stress induction, p53 is normally activated and translocated to the nucleus. Thus, HHV-6B-infection may potentially inactivate p53 by sequestering it in the cytoplasm. To determine whether Ser46 phosphorylated p53 was present in the nucleus or the cytoplasm during infection, HCT116 cells were infected and lysed at 48 hpi followed by separation into a cytoplasmic and a nuclear fraction. Importantly, Ser46 phosphorylated p53 was present in the nucleus (Figure 3B), although p53 is predominantly located in the cytoplasm of the infected cells (Figure 1A and 1B). The inability of HHV-6B-infected cells to undergo p53-dependent cell death may therefore not be solely due to p53 sequestration in the cytoplasm.

To address the possibility that p53 could be activated further by DNA damage stimuli during infection, HCT116 cells were either mock-infected or HHV-6B-infected for 24 hrs and γ-irradiated followed by 24 hrs of incubation. Cells were lysed and examined by Western blotting with antibodies against p53 or pSer15 (Figure 3C). The level of Ser15 phosphorylation did not increase further in HHV-6B-infected cells after γ irradiation. This suggests that p53 is not activated further after DNA damage in HHV-6B-infected cells.

To determine if the observed discrepancy between WB fractionations (Figure 2B) and confocal microscopy (Figure 1A and 1B) was due to epitope masking during confocal preparations, MOLT3 cells were either mock-treated or infected with HHV-6B and analyzed by confocal microscopy using FL393 and DO-7, two different anti-p53 antibodies. This analysis showed that FL393 only recognized cytoplasmic p53 during infection, whereas the DO-7 recognized both cytoplasmic and a small fraction of nuclear p53 (Figure 3D and 3E). To address whether this nuclear p53 could represent phosphorylated p53, we also stained mock-treated and HHV-6B-infected cells with anti-phospho-Ser15 antibody. This analysis demonstrated a punctuated, nuclear staining pattern resembling that observed with the DO-7 antibody (Figure 3F).

To rule out that p53 could translocate to the nucleus after DNA-damage stimuli in HHV-6B-infected cells, MOLT3 cells with or without HHV-6B infection were either mock-treated or treated with γ radiation for 24 hrs, followed by confocal microscopy analysis with antibodies against p53 (DO-7). This analysis revealed no nuclear translocation of p53 in HHV-6B-infected cells (Figure 3G).

**U19 Protein Inhibits p53-dependent Checkpoint Arrest**

We have previously demonstrated that HHV-6B transcribes mRNA from the *U19* ORF and that a FLAG-tagged U19 protein can be produced in trans [39]. We had noticed that the protein product from the *U19* ORF induced a cell cycle profile with reduced G1-arrest. To confirm that U19 could induce an impaired G1-checkpoint arrest and a p53-deficient-like cell cycle profile, we performed cell cycle analyses of the stable U19-expressing cell line, HCT116-U19-S [39], using a nuclear isolation method with DAPI stain (NIM-DAPI) flow cytometry and compared with the profiles obtained from HCT116-p53−/− cells. As expected, HCT116-p53−/− cells demonstrated a drop in the proportion of cells in G1, and an increase in the S and G2 population (Figures 4A and 4B), probably caused by a lack of p53-induced checkpoint arrest in G1/S and G2/M [40]. Analysis of the U19-S cells yielded similar results with a drop in G1 and an increase in S and G2, indicating a dysfunctional checkpoint arrest (Figures 4A and 4B). These data indicated that cells expressing U19, despite their elevated levels of p53, behaved similar to cells lacking p53. P53-dependent checkpoint arrest is conveyed through p21, which inhibits cyclin-dependent kinase 2 (CDK2). CDK2 is an inhibitor of Rb, which acts as an inhibitor of the transcription factor E2F-1. E2F-1 is needed for progression into the S-phase of the cell cycle. If U19 inhibits p53 activity during normal cell cycle, no p21 transcription would be expected in these cells. We examined the ability of HCT116-U19-S cells to transactivate a p21 promoter-driven luciferase gene. Expression of the WWP-luc plasmid containing the wt WAF1 (p21) gene in HCT116 wt cells led to a three-fold increase in luciferase activity after γ irradiation when compared with untreated cells (Figure 4C). When WWP-luc was expressed in HCT116-U19-S cells, no induction of luciferase activity after γ irradiation was detectable (Figure 4C). This finding suggests that U19-expressing cells are deficient in normal p53-induced checkpoint arrest.

To further address p53 target genes, we conducted real-time PCR with *MDM2* specific primers on mRNA from wt cells, U19S cells or p53−/− cells either mock-treated or cells treated with γ radiation. Similarly to our observations with the WWP-luc assay, we found γ-induction of *MDM2* in wt cells but not in U19S or p53−/− cells (Figure 4D).

**HHV-6B Protein U19 Rescues Cells from p53-dependent Cell Death**

To determine if p53 in U19-expressing cells were broadly functionally inactive, lentiviral-transduced U19 cells (U19-LV) were γ-irradiated and analyzed by Western blotting with antibodies against p53, PUMA and PARP. As expected, mock-LV cells showed increased levels of p53 after γ irradiation. This correlated with an increase in expression of PUMA and an increase in cleavage of PARP, indicating induction of apoptosis. In contrast, U19-LV cells had increased levels of p53, and did not upregulate PUMA or cleave PARP upon γ radiation (Figures 5A and 5B). Moreover, when wt, U19S or p53−/− cells were analyzed by real-time PCR for *PUMA* mRNA induction after γ irradiation, only wt cells responded with increased levels of *PUMA* mRNA (Figure 5C).

To determine if U19-expressing cells could still die through p53-independent death pathways, U19-LV and mock-LV cells were treated with UV radiation and MG132. Similarly to observations with HHV-6B-infected cells, U19-expressing cells died from these treatments (Figures 5D and 5E). To examine whether the inhibition of p53 activity was due to reduced post-translational phosphorylations, mock-LV and U19-LV cells were γ-irradiated and cell lysates were subsequently analyzed by Western blotting with antibodies against p53 pSer15 and pSer46. Both mock and U19 cells showed increased phosphorylation on both Ser15 and Ser46 following γ irradiation (Figure 5F). This demonstrated that although p53 is phosphorylated on Ser46, it does not mediate cell death in the presence of the HHV-6B U19 protein.

Recently, new types of programmed cell death have been described, most prominently the non-apoptotic, necrotic-like cell death termed necroptosis [41]. This type of cell death appears to act as a back-up mechanism when apoptosis fails, such as during herpesvirus-infections, where caspase-8 is often blocked by viral proteins [42,43]. Necroptosis can be induced by inhibition of apoptosis, using the pan-caspase inhibitor zVAD-fmk. Conversely, necroptosis is dependent on RIP1 kinase activity, which can be inhibited by necrostatin-1 ( nec-1).

In order to determine whether U19 expressing cells were capable of dying through necroptosis following γ irradiation, wt and U19-LV cells where treated with or without zVAD or nec-1 followed by γ radiation and subsequent incubation for 24 or 48 hrs. The cells were analyzed for intracellular ATP levels as an indirect measurement of cell death. Alone, zVAD or nec-1 induced a minor reduction in cell death (Figure 5G), which was specifically pronounced after 24 hrs treatment when the inhibitors...
were added together (Figure 5G). In agreement with analysis by WB (Figure 5A and B), U19-LV cells did not show any signs of cell death after γ irradiation, and this was not changed by the presence of zVAD (Figure 5G).

To determine if the inability of U19 to block UV-induced cell death was due to a switch to necroptosis, we treated wt and U19-LV cells with or without zVAD or nec-1 followed by UV treatment and incubation for 24 or 48 hrs. Cell death was measured by ATP-analysis. Both wt and U19-LV cells died from UV treatment (Figure 5H). Surprisingly there was little or no effect from treating the cells with zVAD, nec-1 or zVAD/nec-1. However, the U19-LV cells did appear to die with slightly delayed kinetics when compared with wt cells.

In order to verify that UV radiation killed cells in a p53-independent manner and γ radiation killed the cells in a p53-dependent manner, we treated HCT116 p53−/− cells with or without UV radiation or γ radiation for 24 hrs and analyzed the cells by ATP-assay. As expected, p53−/− cells died after UV treatment, but were unaffected after γ irradiation (Figure 5I).
Figure 5. U19 inhibits p53-dependent apoptosis. (A) Western blot analyses with antibodies against p53, PUMA, and GAPDH on lysates from HCT116 cells transduced with an empty or a U19 lentivirus vector and treated with or without γ radiation (30 Gy) followed by incubation for 24 hrs. (B) Western blot analyses with antibodies against PARP and GAPDH on lysates from HCT116 cells transduced with an empty or a U19 lentivirus vector and treated with or without γ radiation (30 Gy) followed by incubation for 24 hrs. (C) Real-time PCR on mRNA from HCT116 wt, U19S and p53−/− cells with PUMA or TBP specific primers. PUMA mRNA levels are represented relative to TBP. Measurements were performed in duplicate. Two independent experiments is shown. (D) Western blot analyses with antibodies against PARP and GAPDH on lysates from HCT116 cells transduced with an empty or a U19 lentivirus vector and treated with or without MG132 for 24 hrs. (E) Western blot analyses with antibodies against p53 and GAPDH on lysates from HCT116 cells transduced with an empty or a U19 lentivirus vector and treated with or without γ radiation (30 Gy) followed by 24 hrs of incubation. (G & H) HCT116 mock-LV (wt) and U19-LV (U19) cells where treated with or without zVAD, nec-1 or both for 1 hr followed by γ irradiation (30 Gy) or γ irradiation (60 J/cm2) for 24 hrs. Cell viability was assessed by measuring intracellular ATP levels. Data are shown as % dead cells calculated relative to untreated cells. Measurements were performed in duplicate. An average of three independent experiments is shown. Error bars represent SD. (I) HCT116 p53−/− cells were treated with or without γ radiation (30 Gy) or UV (60 J/cm2) for 24 hrs followed by analysis of intracellular ATP levels. Measurements were performed in duplicate. An average of three independent experiments is shown. Error bars represent SD. doi:10.1371/journal.pone.0059223.g005

Discussion

The tumor suppressor protein p53 is an important cellular antiviral factor that may induce apoptosis in infected cells, if not blocked by viral or cellular proteins. Many viruses have therefore evolved mechanisms to evade the response from p53 [44]. Since HHV-6B-infected cells do not die despite elevated levels of p53, we speculated that p53 might be inactivated during infection. To address this question, we performed both mRNA and protein analysis during cell death induced by p53-dependent and -independent pathways. These experiments demonstrated that HHV-6B infection rescued the cells from p53-dependent, but not p53-independent cell death.

Takemoto et al. [26] have previously demonstrated that infection of MOLT3 cells by the HST strain rescued the cells from UV radiation-induced cell death. Our results showed that infection of both permissive MOLT3 cells and non-permissive HCT116 cells by the PL1 strain failed to protect cells against UV radiation-induced apoptosis. Infection did reduce the rate of cell death at low-level UV-treatment, but death was still correlated to the amount of UV-treatment similar to untreated cells. The discrepancy between the previous study and our study remains unexplained, but might be caused by the use of different strains of virus. Alternatively, the type of UV radiation might have been different. Either way, this is an interesting observation that requires further investigation with comparison of different strains of virus.

Most of the functional activities of p53 occur in the nucleus, where p53 acts as a transcriptional activator of genes involved in numerous processes, including cell cycle arrest, pro-inflammation and cell death. Although p53 is primarily found in the cytoplasm during infection, we showed that p53 Ser46 is almost exclusively found in the nucleus. Sequestration of p53 in the cytoplasm may therefore not alone explain the apparent lack of p53 effector functions. Ser15 phosphorylation is primarily involved in stabilization of p53 and induction of cell cycle arrest, whereas additional phosphorylation on Ser46 is important for cells to undergo apoptosis [38,45]. We found that Ser46 was markedly phosphorylated similar to that observed for other p53-Ser residues examined [24,36]. This demonstrated that nuclear p53 contains pro-apoptotic modifications, yet the cells did not die. The reasons for this remain to be defined.

We were able to demonstrate that U19 expression led to a cell cycle profile resembling that of p53 knock-out cells. This is in agreement with our findings that U19-expressing cells fail to transcribe p21. The observed cell cycle profile in U19-expressing cells is not similar to the profile obtained from HHV-6B-infected cells [33]. This may not be surprising as HHV-6B-infected cells have been shown to arrest in G1 independently of p53 [24,33]. Other viral proteins must thus be responsible for the induction of G1 arrest during the infection. Furthermore, we found that U19 expression induced stabilization and functional inactivation of p53. In contrast to wt cells, but similar to HHV-6B-infected cells, the U19-expressing cells did not upregulate PUMA expression upon γ irradiation nor did they die or arrest from the accumulation of high level of p53. Nevertheless, cells expressing U19 were still able to die from p53-independent apoptosis. Switching the cells to the necroptotic pathway by the use of zVAD did not sensitize U19-expressing cells to γ-induced cell death. This indicates that after γ irradiation both the apoptotic and necroptotic pathways are dependent on p53-signaling. UV-induced cell death was inhibited by neither zVAD nor nec-1. Surprisingly co-treatment with zVAD and nec-1 also failed to rescue the cells from UV-induced cell death. UV radiation may thus induce death through another pathway than apoptosis or necroptosis.

In conclusion, U19 plays an important role in the rescue of p53-induced cell death during HHV-6B infection. Despite this, U19 may not be solely responsible for p53 inactivation during HHV-6B infection. Since U19 is an early gene, HHV-6B may encode an immediate early inhibitor of p53, or include a p53 inhibitory protein in the virion, thereby carrying it into newly infected cells. The latter hypothesis is supported by the finding that the p53-interacting protein U14, is present in the virion [46]. Alternatively, the virus may instead need the activities of p53 at an early stage during infection. This is known from other viruses, including HCMV [22,23].

Supporting Information

Table S1 Genes used for heatmap analysis. Raw data from the array analysis are shown. (DOCX)

Acknowledgments

We thank Drs. Paolo Lusso for the PL-1 strain of HHV-6B, Bert Vogelstein and Kenneth Kizlner for the WWP-d fluorescent plasmid, HCT116 wt, and p53−/− cells, Zwi Berneman for MOLT3 cells, and Mogens Kruhøffer and Torben F. Ørntoft for performing the GeneChip analyses.

Author Contributions

Provided input on the manuscript: JMLM MHS BB, ROB BO JGM TH. Conceived and designed the experiments: EK-O BO PH. Performed the experiments: EK-O JMLM MHS BB ROB. Analyzed the data: EK-O JMLM PH. Contributed reagents/materials/analysis tools: JGM TH PH. Wrote the paper: EK-O PH.
References

1. Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, et al. (1989) Seroprevalence of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 27: 631–633.

2. Ward KN, Gray JJ, Fotheringham MW, Sheldon MJ (1993) IgG antibodies to human herpesvirus-6 in young children: changes in avidity of antibody correlate with time after infection. J Med Virol 39: 131–138.

3. Kondo K, Kondo T, Okano T, Takahashi M, Yamanishi K (1991) Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 72: 1401–1408.

4. Luppi M, Barozzi P, Morris C, Maiorana A, Garber R, et al. (1999) Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo. J Clin Virol 73: 754–759.

5. Arakelch-JH, Medveczky MM, Luka J, Hadley SH, Laegmayer A, et al. (2010) The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci USA (107): 5563–5568.

6. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, et al. (2008) Chromosomal Integration of Human Herpesvirus 6 Is the Major Mode of Congenital Human Herpesvirus 6 Infection. Pediatrics 122: 513–520.

7. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, et al. (1990) Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1: 1065–1067.

8. Yamashita N, Morishima T (2005) HHV-6 and seizures. Herpes 12: 86–49.

9. Yoshikawa T, Suga S, Asano Y, Nakashima T, Yazaki T, et al. (1991) Human herpesvirus-6 infection in bone marrow transplantation. Blood 78: 1301–1304.

10. Fotheringham J, Donati D, Akyanu N, Fogdell-Hahn A, Vortmeyer A, et al. (2007) U20 Is Responsible for Human Herpesvirus 6B Inhibition of Tumor Necrosis Factor Receptor-Dependent Signaling and Apoptosis. J Virol 81: 11483–11492.

11. Oster B, Bundgaard B, Hopp TR, Hollberg P (2000) Human herpesvirus 6B inhibits phosphorylation of p53 in its regulatory domain by a CK2-independent pathway. J Virol 74 Suppl 1: S63–S68.

12. D’Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, et al. (2002) Human herpesvirus 6B infection causes aberrant accumulation of p53 and prevents apoptosis. J Gen Virol 83: 869–879.

13. Brattnig MG, Fine WD, khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751–1756.

14. Minowada J, Onuma T, Moore GE (1972) Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49: 891–895.

15. Oster B, Hollberg P (2002) Viral gene expression patterns in human herpesvirus 6B-infected T cells. J Virol 76: 7578–7586.

16. Tavano VA, Bundgaard B, Hollberg P (2009) Human herpesvirus-6B induces expression of the human endogenous retrovirus K10-encoded superantigen. J Clin Virol 46: 15–19.

17. Fox MH (1980) A model for the computer analysis of synonymous DNA distributions obtained by flow cytometry. Cytometry 1: 71–77.

18. Kofod-Olsen E, Ross-Hansen K, Schleimann MH, Jensen DK, Moller JM, et al. (2012) LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 31: 1027–1031.

19. Li Y, Jenkins CW, Nichols MA, Xiong Y (1994) Cell cycle expression and p53 stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J Biol Chem 282: 29284–29295.

20. Schleimann MH, Moller JM, Argente M, Gruhler A, Hollsberg P (2005) The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci USA (107): 5563–5568.

21. Zhang Z, Evers DL, McCarville JF, Danonel JC, Huong SM, et al. (2006) Evidence that the human cytomegalovirus IE2-46 protein binds mdm2 and facilitates mdm2 degradation. J Virol 80: 3833–3843.

22. Casavant NC, Luo MH, Rosenke K, Winegardner T, Ziravska A, et al. (2006) Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol 80: 8390–8401.

23. Hennemann H, Rosenke K, O’Dowd JM, Fortunato EA (2009) The presence of p53 influences the expression of multiple human cytomegalovirus genes at early times postinfection. J Virol 83: 4316–4325.

24. Oster B, Bundgaard B, Hollberg P (2003) Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells. J Virol 79: 1961–1965.

25. Schleimann MH, Moller JM, Kofod-Olsen E, Hollberg P (2009) Direct Repeat 6 from human herpesvirus-6B encodes a nuclear protein that forms a complex with the viral DNA processing factor p11. PLoS ONE 4: e7437.

26. Takemoto M, Mori Y, Ueda K, Kondo K, Yamanishi K (2004) Producive human herpesvirus 6 infection causes aberrant accumulation of p53 and prevents apoptosis. J Gen Virol 85: 869–879.

27. Levine AJ (2009) The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53, Virology 304: 285–293.

28. Upton JW, Kaiser WJ, Mocarski ES (2012) Virology 384: 285–293.

29. Pham T, Hsu HC, Shen P, Kim NK, Desai SS, et al. (2006) Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion. J Virol 79: 13057–13046.

30. U20 Protein from HHV-6B Inhibits Cell Death